Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SEOM clinical guidelines on nutrition in cancer patients (2018).
de Las Peñas R, Majem M, Perez-Altozano J, Virizuela JA, Cancer E, Diz P, Donnay O, Hurtado A, Jimenez-Fonseca P, Ocon MJ. de Las Peñas R, et al. Among authors: diz p. Clin Transl Oncol. 2019 Jan;21(1):87-93. doi: 10.1007/s12094-018-02009-3. Epub 2019 Jan 8. Clin Transl Oncol. 2019. PMID: 30617923 Free PMC article.
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy.
De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona JV, Isla D. De Castro J, et al. Among authors: diz p. Clin Transl Oncol. 2017 Feb;19(2):219-226. doi: 10.1007/s12094-016-1527-8. Epub 2016 Jul 1. Clin Transl Oncol. 2017. PMID: 27371031
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.
Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C, Felip E. Remon J, et al. Among authors: diz p. Clin Transl Oncol. 2017 Dec;19(12):1537-1542. doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28. Clin Transl Oncol. 2017. PMID: 28660482
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M. Arriola E, et al. Among authors: diz p. BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7. BMC Cancer. 2018. PMID: 29382302 Free PMC article.
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M. Isla D, et al. Among authors: diz p. Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. Epub 2018 Dec 1. Lung Cancer. 2019. PMID: 31446990 Clinical Trial.
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.
Vicente-Baz D, Paredes A, Morán T, Massuti B, Reguart N, Álvarez R, Insa A, Juan-Vidal O, Artal Á, Esteban E, García-Campelo R, Ortega-Granados AL, Diz P, González-Larriba JL, Terrasa J, de Las Peñas R, Rodríguez-Abreu D, Callejo Á, Márquez G, Provencio M. Vicente-Baz D, et al. Among authors: diz p. Rev Esp Patol. 2020 Jul-Sep;53(3):140-148. doi: 10.1016/j.patol.2019.11.002. Epub 2020 Jan 13. Rev Esp Patol. 2020. PMID: 32650965
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.
Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M. Romero A, et al. Among authors: diz p. Mol Oncol. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. Epub 2020 Nov 13. Mol Oncol. 2021. PMID: 33107189 Free PMC article.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, García-Giron C, Hidalgo J, Aguado C, González JG, Esteban E, Gómez-Aldavarí L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Sánchez Peña AM, Bosch-Barrera J, Gastaldo AS, Núñez NF, Del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V. Provencio M, et al. Among authors: diz p. BMC Cancer. 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. BMC Cancer. 2021. PMID: 33676426 Free PMC article.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres JM, Majem M, Diz P, Gordo R, Coca M, de Castro J. Bernabé-Caro R, et al. Among authors: diz p. Oncotarget. 2022 Jun 15;13:812-827. doi: 10.18632/oncotarget.28244. eCollection 2022. Oncotarget. 2022. PMID: 35720977 Free PMC article.
130 results